218 related articles for article (PubMed ID: 26556305)
1. A Nanobody Activation Immunotherapeutic that Selectively Destroys HER2-Positive Breast Cancer Cells.
Gray MA; Tao RN; DePorter SM; Spiegel DA; McNaughton BR
Chembiochem; 2016 Jan; 17(2):155-8. PubMed ID: 26556305
[TBL] [Abstract][Full Text] [Related]
2. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session.
Deken MM; Kijanka MM; Beltrán Hernández I; Slooter MD; de Bruijn HS; van Diest PJ; van Bergen En Henegouwen PMP; Lowik CWGM; Robinson DJ; Vahrmeijer AL; Oliveira S
J Control Release; 2020 Jul; 323():269-281. PubMed ID: 32330574
[TBL] [Abstract][Full Text] [Related]
3. Disparities between Antibody Occupancy, Orientation, and Cytotoxicity in Immunotherapy.
Ta AN; Tennyson RL; Aceveda DC; McNaughton BR
Chembiochem; 2020 Sep; 21(17):2435-2439. PubMed ID: 32274876
[TBL] [Abstract][Full Text] [Related]
4. Development and Characterization of a Humanized Anti-HER2 Antibody HuA21 with Potent Anti-Tumor Properties in Breast Cancer Cells.
Li R; Hu S; Chang Y; Zhang Z; Zha Z; Huang H; Shen G; Liu J; Song L; Wei W
Int J Mol Sci; 2016 Apr; 17(4):563. PubMed ID: 27092488
[TBL] [Abstract][Full Text] [Related]
5. HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail".
Menéndez JA; Vázquez-Martín A; Ropero S; Colomer R; Lupu R
Clin Transl Oncol; 2006 Nov; 8(11):812-20. PubMed ID: 17134970
[TBL] [Abstract][Full Text] [Related]
6. Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells.
Menendez JA; Vazquez-Martin A; Colomer R; Brunet J; Carrasco-Pancorbo A; Garcia-Villalba R; Fernandez-Gutierrez A; Segura-Carretero A
BMC Cancer; 2007 May; 7():80. PubMed ID: 17490486
[TBL] [Abstract][Full Text] [Related]
7. Tribody [(HER2)
Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
Front Immunol; 2018; 9():814. PubMed ID: 29725336
[TBL] [Abstract][Full Text] [Related]
8. Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.
Kubo M; Morisaki T; Kuroki H; Tasaki A; Yamanaka N; Matsumoto K; Nakamura K; Onishi H; Baba E; Katano M
Anticancer Res; 2003; 23(6a):4443-9. PubMed ID: 14666732
[TBL] [Abstract][Full Text] [Related]
9. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients.
Suzuki E; Niwa R; Saji S; Muta M; Hirose M; Iida S; Shiotsu Y; Satoh M; Shitara K; Kondo M; Toi M
Clin Cancer Res; 2007 Mar; 13(6):1875-82. PubMed ID: 17363544
[TBL] [Abstract][Full Text] [Related]
10. Cardiac dysfunction associated with trastuzumab.
Smith KL; Dang C; Seidman AD
Expert Opin Drug Saf; 2006 Sep; 5(5):619-29. PubMed ID: 16907652
[TBL] [Abstract][Full Text] [Related]
11. Generation of a nanobody against HER2 tyrosine kinase using phage display library screening for HER2-positive breast cancer therapy development.
Lamtha T; Tabtimmai L; Bangphoomi K; Kiriwan D; Malik AA; Chaicumpa W; van Bergen En Henegouwen PMP; Choowongkomon K
Protein Eng Des Sel; 2021 Feb; 34():. PubMed ID: 34908139
[TBL] [Abstract][Full Text] [Related]
12. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.
Upton R; Banuelos A; Feng D; Biswas T; Kao K; McKenna K; Willingham S; Ho PY; Rosental B; Tal MC; Raveh T; Volkmer JP; Pegram MD; Weissman IL
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34257155
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of [
Ducharme M; Hall L; Eckenroad W; Cingoranelli SJ; Houson HA; Jaskowski L; Hunter C; Larimer BM; Lapi SE
Mol Pharm; 2023 Sep; 20(9):4629-4639. PubMed ID: 37552575
[TBL] [Abstract][Full Text] [Related]
14. Perceptions of Herceptin: a monoclonal antibody for the treatment of breast cancer.
Dillman RO
Cancer Biother Radiopharm; 1999 Feb; 14(1):5-10. PubMed ID: 10850281
[TBL] [Abstract][Full Text] [Related]
15. Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies.
Frank RT; Edmiston M; Kendall SE; Najbauer J; Cheung CW; Kassa T; Metz MZ; Kim SU; Glackin CA; Wu AM; Yazaki PJ; Aboody KS
PLoS One; 2009 Dec; 4(12):e8314. PubMed ID: 20016813
[TBL] [Abstract][Full Text] [Related]
16. HER2 and surgery: more questions to answer.
Spigel DR
Lancet; 2003 Aug; 362(9383):502-3. PubMed ID: 12932377
[No Abstract] [Full Text] [Related]
17. Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer.
Li F; Liu S
Front Immunol; 2022; 13():1083462. PubMed ID: 36601109
[TBL] [Abstract][Full Text] [Related]
18. Mediterranean diet, olive oil and cancer.
Colomer R; Menéndez JA
Clin Transl Oncol; 2006 Jan; 8(1):15-21. PubMed ID: 16632435
[TBL] [Abstract][Full Text] [Related]
19. Nanobody-Based Theranostic Agents for HER2-Positive Breast Cancer: Radiolabeling Strategies.
Hrynchak I; Santos L; Falcão A; Gomes CM; Abrunhosa AJ
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639086
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer.
Niculescu-Duvaz I
Curr Opin Mol Ther; 2010 Jun; 12(3):350-60. PubMed ID: 20521224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
